MyMD
  • Contact MyMD
  • About Us
    • Team
  • Pipeline
    • MYMD-1®
    • Supera-CBD
  • Research
    • Clinical Trials
  • Investors
  • News
    • MyMD News
    • Press Releases
    • Thought leadership
    • Perspectives
  • Subscribe
  • Contact MyMD

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Info
    • Overview
    • Management Team
    • Presentations
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
    • Board Diversity Matrix
  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Email Alerts
Apr 28, 2021 10:13am EDT

Johns Hopkins Medicine Researchers to Present Data on MyMD Pharmaceuticals’ Supera-CBD at the 3rd Annual Neuroimmunology Drug Development Summit

Apr 22, 2021 9:20am EDT

MyMD Pharmaceuticals Announces Issuance of Allowance from United States Patent and Trademark Office for Synthetic Cannabinoid Compounds

Apr 19, 2021 9:00am EDT

MyMD Pharmaceuticals Begins Trading on Nasdaq

  • arrow_back
  • 1
  • 2
  • 3
  • 4
  • 5
rss_feed News RSS
  • Email Alerts
  • Contacts
  • RSS News Feed

Connect with MyMD Pharmaceuticals

Subscribe to stay up-to-date on new developments at MyMD.

Contact Us

MyMD

© 2023 MyMD Pharmaceuticals™. All Right Reserved

  • Privacy Policy
  • Terms & Conditions

This site is not intended to provide medical advice or to suggest that any product mentioned is safe or efficacious for any disease or condition.

News & Resources

View a collection of articles, thought leadership content and industry news.

Subscribe to receive MyMD announcements
  • This field is for validation purposes and should be left unchanged.